Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease

References

• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and Long-Term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):1–8. doi: 10.1161/CIR.0000000000000484.
   Web of Science ®Google Scholar
• Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348–1407. doi: 10.1253/circj.CJ-19-1094.
   PubMed Web of Science ®Google Scholar
• Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16(7):391–405. doi: 10.1038/s41584-020-0426-0.
   PubMed Web of Science ®Google Scholar
• Gorelik M, Chung SA, Ardalan K, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of Kawasaki disease. Arthritis Care Res (Hoboken). 2022;74(4):538–548. doi: 10.1002/acr.24838.
   PubMed Web of Science ®Google Scholar
• Hsieh LE, Song J, Tremoulet AH, et al. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells. Clin Exp Immunol. 2022;208(3):361–371. doi: 10.1093/cei/uxac046.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–2612. doi: 10.1161/CIRCULATIONAHA.105.592865.
   PubMed Web of Science ®Google Scholar
• Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–137. doi: 10.1007/s00431-006-0223-z.
   PubMed Web of Science ®Google Scholar
• Kaya Akca U, Arslanoglu Aydin E, Aykan HH, et al. Comparison of IVIG resistance predictive models in Kawasaki disease. Pediatr Res. 2022;91(3):621–626. doi: 10.1038/s41390-021-01459-w.
   PubMed Web of Science ®Google Scholar
• Jakob A, von Kries R, Horstmann J, et al. Failure to predict high-risk Kawasaki disease patients in a population-based study cohort in Germany. Pediatr Infect Dis J. 2018;37(9):850–855. doi: 10.1097/INF.0000000000001923.
   PubMed Web of Science ®Google Scholar
• Davies S, Sutton N, Blackstock S, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child. 2015;100(4):366–368. doi: 10.1136/archdischild-2014-307397.
   PubMed Web of Science ®Google Scholar
• Piram M, Darce Bello M, Tellier S, et al. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Sci Rep. 2020;10(1):3125. doi: 10.1038/s41598-020-59972-7.
   PubMed Web of Science ®Google Scholar
• Liu J, Ye B, Su D, et al. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki disease before and after therapy. Clin Rheumatol. 2023;42(1):167–177. doi: 10.1007/s10067-022-06366-x.
   PubMed Web of Science ®Google Scholar
• Kitoh T, Ohara T, Muto T, et al. Increased pentraxin 3 levels correlate with IVIG responsiveness and coronary artery aneurysm formation in Kawasaki disease. Front Immunol. 2021;12:624802. doi: 10.3389/fimmu.2021.624802.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Muto T, Masuda Y, et al. Procalcitonin as a biomarker of unresponsiveness to intravenous immunoglobulin for Kawasaki disease. Pediatr Infect Dis J. 2020;39(9):857–861. doi: 10.1097/INF.0000000000002716.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Suzuki Y, Okada S, et al. Utility of soluble CD163 in the clinical management of patients with Kawasaki disease. Front Pediatr. 2020;8:148. doi: 10.3389/fped.2020.00148.
   PubMed Web of Science ®Google Scholar
• Muto T, Nakamura N, Masuda Y, et al. Serum free carnitine levels in children with Kawasaki disease. Pediatr Int. 2022;64(1):e14849. doi: 10.1111/ped.14849.
   PubMed Web of Science ®Google Scholar
• Lam JY, Song MS, Kim GB, et al. Intravenous immunoglobulin resistance in kawasaki disease patients: prediction using clinical data. Pediatr Res. 2023;16:1–6. doi: 10.1038/s41390-023-02519-z.
   Google Scholar
• Abdelhakam DA, Badr FM, Abd El Monem Teama M, et al. Serum amyloid A, ferritin and carcinoembryonic antigen as biomarkers of severity in patients with COVID-19. Biomed Rep. 2022;16(2):13. doi: 10.3892/br.2021.1496.
   PubMed Web of Science ®Google Scholar
• Hong L, Herjan T, Bulek K, et al. Mechanisms of corticosteroid resistance in type 17 asthma. J Immunol. 2022;209(10):1860–1869. doi: 10.4049/jimmunol.2200288.
   PubMed Web of Science ®Google Scholar
• Shridas P, Patrick AC, Tannock LR. Role of serum amyloid a in abdominal aortic aneurysm and related cardiovascular diseases. Biomolecules. 2021;11(12):1883. doi: 10.3390/biom11121883.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Hu Z, Li Y, et al. Serum amyloid a delivers retinol to intestinal myeloid cells to promote adaptive immunity. Science. 2021;373(6561):eabf9232. doi: 10.1126/science.abf9232.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation. 2005;111(1):38–43. doi: 10.1161/01.CIR.0000151311.38708.29.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Fuse S, Sakamoto N, et al. A new Z score curve of the coronary arterial internal diameter using the Lambda-Mu-Sigma method in a pediatric population. J Am Soc Echocardiogr. 2016;29(8):794–801.e29. doi: 10.1016/j.echo.2016.03.017.
   PubMed Web of Science ®Google Scholar
• Li C, Wu S, Shi Y, et al. Establishment and validation of a multivariate predictive scoring model for intravenous immunoglobulin-resistant Kawasaki disease: a study of children from two centers in China. Front Cardiovasc Med. 2022;9:883067. doi: 10.3389/fcvm.2022.883067.
   PubMed Web of Science ®Google Scholar
• Zheng X, Wu W, Zhang Y, et al. Changes in and significance of platelet function and parameters in Kawasaki disease. Sci Rep. 2019;9(1):17641. doi: 10.1038/s41598-019-54113-1.
   PubMedGoogle Scholar
• Wu S, Long Y, Chen S, et al. A new scoring system for prediction of intravenous immunoglobulin resistance of Kawasaki disease in infants under 1-year old. Front Pediatr. 2019;7:514. doi: 10.3389/fped.2019.00514.
   PubMed Web of Science ®Google Scholar
• Cheng F, Kang L, Zhang F, et al. Analysis of hyperbilirubinemia in patients with Kawasaki disease. Medicine. 2020;99(36):e21974. doi: 10.1097/MD.0000000000021974.
   PubMed Web of Science ®Google Scholar
• Hara T, Nakashima Y, Sakai Y, et al. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol. 2016;186(2):134–143. doi: 10.1111/cei.12832.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Katkar GD, Shimizu C, et al. An artificial intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. Nat Commun. 2022;13(1):2687. doi: 10.1038/s41467-022-30357-w.
   PubMed Web of Science ®Google Scholar
• Whitin JC, Yu TT, Ling XB, et al. A novel truncated form of serum amyloid a in kawasaki disease. PLOS One. 2016;11(6):e0157024. doi: 10.1371/journal.pone.0157024.
   PubMed Web of Science ®Google Scholar
• Nandi A, Pal P, Basu S. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study. Rheumatol Int. 2019;39(10):1797–1801. doi: 10.1007/s00296-019-04375-9.
   PubMed Web of Science ®Google Scholar
• Porritt RA, Chase Huizar C, Dick EJ, et al. Inhibition of IL-6 in the LCWE mouse model of Kawasaki disease inhibits acute phase reactant serum amyloid a but fails to attenuate vasculitis. Front Immunol. 2021;12:630196. doi: 10.3389/fimmu.2021.630196.
   PubMed Web of Science ®Google Scholar
• Anthony D, Seow HJ, Uddin M, et al. Serum amyloid a promotes lung neutrophilia by increasing IL-17A levels in the mucosa and γδ T cells. Am J Respir Crit Care Med. 2013;188(2):179–186. doi: 10.1164/rccm.201211-2139OC.
   PubMed Web of Science ®Google Scholar
• Kuniyoshi Y, Tsujimoto Y, Banno M, et al. Prediction models for intravenous immunoglobulin resistance in Kawasaki disease: a meta-analysis. Pediatrics. 2023;151(5):e2022059175. doi: 10.1542/peds.2022-059175.
   PubMed Web of Science ®Google Scholar